Lumida
/AVIR
⌘K
Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc

AVIR
$4.87USD+3.29%+0.16 today

MARKET CAP

389.7M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$3
$6

AI Summary

Stalk
TrimMedium

In a Stage 3 distribution range, price remains below down-sloping EMAs and the 50 DMA, with rallies failing into resistance and volume contracting on advances. The 3-year uptrend anchors long-term polarity, but medium-term asymmetry favors sellers. Short-term timing offers no clear edge until rallies into the 9/21 EMA zone. Execution should focus on fading strength at these EMAs around the upper boundary of the trading range.

  • Phase II trials showed a 98% sustained virologic response.
  • Strong $379.7M cash position sustains Phase III through 2027.
  • Phase III delays or unfavorable data may stall product approval.
Full analysis →
Insider Trades21 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Mar 11, 2026BuyAVIRAndrea Corcoran60,000$1.24$389.7M-24.50%+75.18%$74.4K+7.86%Trim
Jan 31, 2026SellAVIRJohn VavrickaChief Commercial Officer11,570$4.24$389.7M-24.50%+75.18%$49.1K-5.41%Trim
Jan 31, 2026SellAVIRWayne FosterEVP, Chief Accounting Officer12,132$4.24$389.7M-24.50%+75.18%$51.4K-6.08%Trim
Jan 31, 2026SellAVIRJanet Mj HammondChief Development Officer14,136$4.24$389.7M-24.50%+75.18%$59.9K-4.43%Trim
Jan 31, 2026SellAVIRMaria Arantxa HorgaChief Medical Officer16,073$4.24$389.7M-24.50%+75.18%$68.1K-5.63%Trim
Jan 31, 2026SellAVIRAndrea Corcoran16,104$4.24$389.7M-24.50%+75.18%$68.3K-1.68%Trim
Jan 31, 2026BuyAVIRJean-Pierre SommadossiPresident, CEO, and Chairman406,093$2.02$389.7M-24.50%+75.18%$821.8K+18.61%Trim
Jan 31, 2025SellAVIRJohn VavrickaChief Commercial Officer11,517$3.06$389.7M-24.50%+75.18%$35.2K-4.83%Trim
Jan 31, 2025SellAVIRWayne FosterEVP, Chief Accounting Officer12,062$3.06$389.7M-24.50%+75.18%$36.9K-5.39%Trim
Jan 31, 2025SellAVIRJanet Mj HammondChief Development Officer14,134$3.06$389.7M-24.50%+75.18%$43.3K-4.00%Trim
Jan 31, 2025SellAVIRMaria Arantxa HorgaChief Medical Officer16,071$3.06$389.7M-24.50%+75.18%$49.2K-5.01%Trim
Jan 31, 2025SellAVIRAndrea Corcoran16,102$3.06$389.7M-24.50%+75.18%$49.3K-1.63%Trim
Jan 31, 2025SellAVIRJean-Pierre SommadossiPresident, CEO, and Chairman88,601$3.06$389.7M-24.50%+75.18%$271.1K-8.04%Trim
Sep 17, 2024SellAVIRJean-Pierre SommadossiPresident, CEO, and Chairman57,969$4.04$389.7M-24.50%+75.18%$234.2K-0.33%Trim
Jun 5, 2024SellAVIRJean-Pierre SommadossiPresident, CEO, and Chairman1,006$4.00$389.7M-24.50%+75.18%$4.0K-0.02%Trim
Feb 1, 2024SellAVIRJohn VavrickaChief Commercial Officer11,819$3.84$389.7M-24.50%+75.18%$45.4K-5.08%Trim
Feb 1, 2024SellAVIRWayne FosterEVP, Chief Accounting Officer12,477$3.84$389.7M-24.50%+75.18%$47.9K-5.67%Trim
Feb 1, 2024SellAVIRJanet Mj HammondChief Development Officer14,029$3.84$389.7M-24.50%+75.18%$53.9K-3.81%Trim
Feb 1, 2024SellAVIRAndrea Corcoran15,843$3.84$389.7M-24.50%+75.18%$60.9K-1.63%Trim
Feb 1, 2024SellAVIRMaria Arantxa HorgaChief Medical Officer15,870$3.84$389.7M-24.50%+75.18%$61.0K-5.00%Trim
Feb 1, 2024SellAVIRJean-Pierre SommadossiPresident, CEO, and Chairman56,910$3.85$389.7M-24.50%+75.18%$218.8K-5.88%Trim